[go: up one dir, main page]

WO2003075842A3 - Stable formulations of angiotensin converting enzyme (ace) inhibitors - Google Patents

Stable formulations of angiotensin converting enzyme (ace) inhibitors Download PDF

Info

Publication number
WO2003075842A3
WO2003075842A3 PCT/US2003/006606 US0306606W WO03075842A3 WO 2003075842 A3 WO2003075842 A3 WO 2003075842A3 US 0306606 W US0306606 W US 0306606W WO 03075842 A3 WO03075842 A3 WO 03075842A3
Authority
WO
WIPO (PCT)
Prior art keywords
ace
converting enzyme
angiotensin converting
inhibitors
stable formulations
Prior art date
Application number
PCT/US2003/006606
Other languages
French (fr)
Other versions
WO2003075842A2 (en
Inventor
Scott Stofik
Robert Gwozdz
Christopher L Pelloni
John C James
Original Assignee
Teva Pharmeceuticals Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmeceuticals Usa Inc filed Critical Teva Pharmeceuticals Usa Inc
Priority to AU2003217916A priority Critical patent/AU2003217916A1/en
Publication of WO2003075842A2 publication Critical patent/WO2003075842A2/en
Publication of WO2003075842A3 publication Critical patent/WO2003075842A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A stable pharmaceutical composition comprising a) a therapeutically effective amount of an Angiotensin Converting Enzyme ('ACE') inhibitor which is susceptible to degradation or its salt; b) a greater than stoichiometric amount of an alkali or alkaline earth metal carbonate, relative to the amount of ACE inhibitor or its salt; and c) a pharmaceutically acceptable carrier, including a process for the manufacture of such compositions.
PCT/US2003/006606 2002-03-08 2003-03-06 Stable formulations of angiotensin converting enzyme (ace) inhibitors WO2003075842A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003217916A AU2003217916A1 (en) 2002-03-08 2003-03-06 Stable formulations of angiotensin converting enzyme (ace) inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9384902A 2002-03-08 2002-03-08
US10/093,849 2002-03-08

Publications (2)

Publication Number Publication Date
WO2003075842A2 WO2003075842A2 (en) 2003-09-18
WO2003075842A3 true WO2003075842A3 (en) 2004-01-08

Family

ID=27804229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006606 WO2003075842A2 (en) 2002-03-08 2003-03-06 Stable formulations of angiotensin converting enzyme (ace) inhibitors

Country Status (2)

Country Link
AU (1) AU2003217916A1 (en)
WO (1) WO2003075842A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
EA011862B1 (en) * 2004-03-24 2009-06-30 Актавис Груп Хф. Formulations of ramipril
ES2603856T3 (en) * 2004-03-29 2017-03-01 Les Laboratoires Servier Procedure for preparing a solid pharmaceutical composition
SI21800A (en) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New procedure of synthesis of perindopril
EP1948224B1 (en) 2005-11-17 2014-03-12 Silverstone Pharma Est. Stable formulation of amorphous perindopril salts, a process for their preparation, especially industrial preparation, and their use in the therapy of hypertension
ES2299157T3 (en) * 2006-06-02 2008-05-16 Teva Pharmaceutical Industries Ltd STABLE FORMULATION THAT UNDERSTANDS A PHARMACO SENSITIVE TO HUMIDITY AND PREPARATION PROCEDURE OF THE SAME.
BRPI0621739A2 (en) * 2006-06-02 2011-12-20 Teva Pharma stable formulation consisting of wetting sensitive drugs and their manufacturing procedure
CA2653382A1 (en) * 2006-06-30 2008-01-03 Alphapharm Pty Ltd A stabilised composition comprising ace inhibitors
CN101478983A (en) * 2006-07-10 2009-07-08 特瓦制药工业有限公司 Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
WO2009053994A1 (en) * 2007-10-26 2009-04-30 Matrix Laboratories Limited Process for preparing pure amorphous quinapril hydrochloride
HUE035830T2 (en) 2011-12-21 2018-05-28 Elanco Tiergesundheit Ag New combination
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977159A (en) * 1996-01-15 1999-11-02 Astra Aktiebolag Medical use of an ace-inhibitor for treatment of dyspeptic symptoms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977159A (en) * 1996-01-15 1999-11-02 Astra Aktiebolag Medical use of an ace-inhibitor for treatment of dyspeptic symptoms

Also Published As

Publication number Publication date
AU2003217916A8 (en) 2003-09-22
AU2003217916A1 (en) 2003-09-22
WO2003075842A2 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
CA2261848A1 (en) Cell adhesion inhibitors
WO2002046129A3 (en) Inhibitors of histone deacetylase
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
CA2340052A1 (en) Pharmaceutical compositions containing lipase inhibitors and chitosan
MXPA02003977A (en) INHIBITORS OF agr;L.
IL143545A (en) Thrombin inhibitors and pharmaceutical compositions containing them
DE69831868D1 (en) Antithrombosemittel
WO2003075842A3 (en) Stable formulations of angiotensin converting enzyme (ace) inhibitors
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2003057650A3 (en) Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
DZ3312A1 (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
WO2004012663A3 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
WO2003016248A3 (en) Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
WO2003020200A3 (en) A novel pharmaceutical compound and methods of making and using same
WO2002015892A3 (en) Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors
AU7270798A (en) Antithrombotic agents
AU2001282871A1 (en) Antithrombotic agents
WO2005065047A3 (en) Stable oral composition containing desloratadine
AU2003242592A1 (en) Amide derivatives as inhibitors of the enzymatic activity of renin
MY137878A (en) INHIBITORS OF ALPHA L ß2 INTEGRIN MEDIATED CELL ADHESION
AU8889998A (en) Water soluble analogs and prodrugs of paclitaxel
AU2001252419A1 (en) Thrombin inhibitors
HK1041000A1 (en) Novel pyrimidine derivatives and processes for thepreparation thereof.
EP1027051A4 (en) Antithrombotic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP